• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics (NQ: SRPT )

    123.29 -2.71 (-2.15%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sarepta Therapeutics

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
    Via Benzinga
    This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
    Via Benzinga
    Unveiling 15 Analyst Insights On Sarepta Therapeutics
    Via Benzinga
    Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
    Via Benzinga
    Unveiling 26 Analyst Insights On Sarepta Therapeutics
    Via Benzinga
    How Is The Market Feeling About Sarepta Therapeutics?
    Via Benzinga
    After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
    Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
    Via Benzinga
    Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
    The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
    Via Investor's Business Daily
    2 High-Flying Growth Stocks With Massive Upside Potential
    These innovative drugmakers have potential catalysts ahead. 
    Via The Motley Fool
    Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
    These two could become direct competitors relatively soon. 
    Via The Motley Fool
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
    Via Benzinga
    $100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
    Via Benzinga
    Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
    Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
    Via MarketBeat
    Exposures Product Safety
    Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Smart Money Is Betting Big In SRPT Options
    Via Benzinga
    These 2 Biotech Stocks Are Set to Soar
    Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
    Via The Motley Fool
    Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
    Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
    Via Benzinga
    Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
    The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. 
    Via Investor's Business Daily
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
    Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
    Via MarketBeat
    2 Biotech Stocks to Buy Hand Over Fist in August
    Both of these biotechs are highly innovative companies. 
    Via The Motley Fool
    Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
    These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
    Via Benzinga
    How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
    The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.